Summary The microcirculation plays an important role in bone health. Here, we examine whether albuminuria, a marker of renal microvascular disease, is associated with the risk of hip fracture in older adults (age, 78 years). We find a small independent association in women but not in men. Introduction The microvascular circulation plays an important role in bone physiology. Two studies of middle-aged adults have found that albuminuria (>30 mg albumin/g creatinine), a disorder of the renal microvasculature, is associated with fracture risk. Here, we examine whether albuminuria is related to hip fracture risk and reduced hip bone mineral density (BMD) in older adults with a mean age of 78 years. Methods From the Cardiovascular Health Study (41 % male), 3,110 adults with albuminuria testing were followed up for incident hip fracture for up to 9.5 years. BMD was performed in a subset of 1,208 participants.
Results There were 313 hip fractures during follow-up (7.7 % of men; 11.7 % of women). The incidence rate for men, with and without albuminuria, was 1.43 and 0.93/100 person-years of follow-up (p=0.02); for women, 1.84 and 1.33 (p=0.04). After adjustment for osteoporosis-related factors, frailty and falling, a doubling of albuminuria was significantly associated with hip fracture risk in women (hazard ratio, 1.12, 95 % CI, 1.001-1.25), but not in men. In the subcohort with BMD measurement, increased urine albumin levels were significantly associated with decreased total hip BMD in men (−0.009 g calcium/cm 2 (−0.017, −0.001); p=0.04), but not in women. Conclusions In older women, albuminuria is associated with a small, but statistically significant, increased risk of hip fracture independent of other explanatory factors. No such risk appears to be present in men, although their total hip BMD is lower in association with albuminuria.
Introduction
The microcirculation plays an important role in adult bone health. Endothelial cells from capillaries at sites of bone remodeling release factors associated with mineralization and the coupling of osteoclast and osteoblast function [1] . Disorders of the microcirculation could therefore be associated with bone disease, as evidenced by conditions such as avascular necrosis of the hip. Albuminuria-the excessive excretion of protein in the urine (>30 mg/g creatinine)-is a renal microvascular disorder affecting ∼20 % of people ages >69 years and 30-40 % of similarly aged adults with diabetes [2] . Several lines of evidence suggest that there could be an association of albuminuria with osteoporosis and its worst consequence, hip fracture. First, hip fractures are an age-related disorder, as is albuminuria. Second, albuminuria is associated with elevated levels of inflammation factors [3] . Inflammation plays a role in the development of osteoporosis [4] , an important risk factor for hip fractures. Third, studies of osteoporotic bone [5, 6] and of hip specimens from people having hip replacement surgery for osteoporotic fractures show impaired microvascular blood flow as compared with hip specimens from people having hip replacement surgery for arthritis [7] . Lastly, the factors most commonly associated with albuminuria-diabetes and hypertension-are also risk factors for fractures [8, 9] .
There are two prior investigations of the association of albuminuria and fracture risk. A study from a Scandinavian population cohort identified a significant relationship between albuminuria and nonvertebral fractures in women [10] . That cohort was relatively young (mean age, 63 years) and reported only 75 hip fractures. Risk estimates of hip fracture alone were not done. A second study [11] , also from a relatively young population at high risk for cardiovascular disease, reported an increased risk of hip and pelvis fractures in association with albuminuria. Were albuminuria associated with hip fracture risk, it could inform medical practice as to a role for microvascular disease in fracture risk and possibly could be used for prognostic purposes.
In the present study, we examine a cohort of older individuals who had baseline testing for albuminuria and were followed for incident hip fractures for up to 9.5 years. At baseline, this cohort had a mean age of 78 years, in the range when most hip fractures occur. We determine whether those with albuminuria had a higher risk of hip fracture compared with those without albuminuria. We also examine, in a subcohort that underwent DEXA scanning, the relationship between albuminuria and hip bone mineral density (BMD). We hypothesize that albuminuria is associated with hip fracture risk and with lower hip BMD. Owing to differences in risk factors for hip fractures between men and women, as well as differences in hip BMD and hip fracture rates, and the age at which hip fractures occur, it was decided a priori to conduct analyses separately by gender. This is in keeping with our prior hip fracture studies in the cohort analyzed here [12] .
Methods
The cohort for this study was from the Cardiovascular Health Study (CHS) [13] . In brief, a random sample of individuals, >65 years of age, was invited to participate at four sites. Potential participants were excluded if they were institutionalized, were unable to attend clinic visits, or had illnesses expected to lead to early death. Five thousand two hundred one participants were recruited in 1989-1990 and 687 in 1992-1993 to provide additional representation of African-Americans. All participants signed informed consent at study entry. During follow-up, participants were seen in clinic annually and had telephone contact annually at the midpoint between clinic visits.
Study cohorts
In 1996/1997, 4,412 CHS participants had a clinic or telephone visit. Those doing an interview by phone (n=896) did not provide urine samples. Another 406 participants who attended the clinic did not provide a urine sample. A total of 3,110 (70.5 %) provided a random urine sample and constitute the analytic cohort. Those who did not provide a urine sample were older, shorter, less heavy, expended less energy, were less often male, and fell more often than those who provided a urine sample. They also had more prior fractures, a history of coronary heart disease (CHD), stroke and diabetes, and reported poorer health (data not shown).
In 1994/1995, 1-2 years prior to urine testing for albuminuria, a subset of the cohort (n=1,208) underwent DEXA testing in two of the CHS clinical sites. This subcohort was younger and reported better overall health than the participants who did not have DEXA testing (Appendix).
Demographic and medication information were obtained, including use of alcohol, exercise, and lifestyle activities from which the amount of energy expended per week was derived. Information regarding past falls was collected. Testing for grip strength and walking speed were performed at the 1996/1997 visit. Grip strength was measured in the dominant arm using an isometric dynamometer. The average of three attempts was used. Walking speed was assessed as the time it took to walk 15 feet. Based on these tests and response to questions regarding exhaustion, each participant's frailty status was determined [14] . Frailty was defined using a phenotype that requires >3 of the following criteria: unintended weight loss of >10 lb in the prior year, selfreported exhaustion most of the time, physical activity in the lowest 20 % of the CHS cohort, weakness as measured by grip strength (lowest 20 % of the CHS cohort), and slowness of walking (lowest 20 % in each sex). Those with one or two criteria were "pre-frail," an intermediate syndrome with increased risk for the development of frailty.
Laboratory and radiologic measures
Laboratory tests (glucose, C-reactive protein (CRP), urine albumin, and creatinine) were performed as previously described [15] . As a measure of renal function, cystatin C (cyst C) levels (in milligrams per liter) were measured from stored samples using a BNII nephlometer (Dade Behring Inc., Deerfield, IL) that utilized a particle enhanced immunonephlometric assay (N Latex Cystatin-C). Estimated cystatin-based glomerular filtration rate (ecGFR) was categorized as above or below 60 ml min 
Outcome variable
Hip fracture ascertainment was done through patient selfreport and corroborated from hospital records. Events were defined as incident hip fracture, with follow-up until 30 June 2008. Participants were censored at the time of death. Medicare records of hospitalizations which were coded for hip fractures were also reviewed to identify hip fractures participants did not self report.
Statistical analysis
On account of the small number of hip fractures (n=12) among participants with proteinuria (>299 mg/g creatinine), albuminuria was not dichotomized into micro-and macroalbuminuria.
Baseline characteristics of the cohort were computed by albuminuria status and were compared using χ 2 tests for categorical and binary variables and t tests for mean values of continuous variables. Incidence rates of hip fractures were calculated per 100 participant-years. Kaplan-Meier plots were done to illustrate the event curves by albuminuria status. Log rank testing was used to compare the curves.
Cox proportional hazards models were used to model the association of a doubling of urine albumin per gram creatinine and incident hip fracture. The proportional hazards assumptions were examined using graphical and numerical methods based on scaled Schoenfeld residuals. Urine albumin per gram creatinine was heavily tailed and therefore Winsorized at the 95th percentile and log transformed to base 2. Models were adjusted sequentially: model 1, unadjusted; model 2, demographic factors (race, age, gender, and clinic site); model 3, factors in model 2 plus osteoporosis-related factors, including BMI, smoking status, alcohol use, prevalent coronary heart disease (CHD), hypertension, ecGFR, energy used per week (in kilocalories), and inflammation (CRP); and model 4, factors in model 3 plus factors related to fracture (frailty status and a history of falling in the year preceding the baseline period).
In the DEXA subcohort, linear regression models were constructed to estimate the associations of a doubling of urine albuminuria with total hip and femoral neck BMD. Adjustments were made for factors known to impact bone density: age, race, smoking status, kilocalories energy expenditure, BMI, ecGFR of <60 ml min −1 1.73 m −2 , and diabetes. Analyses were done using R [16] .
Results

Baseline characteristics of the cohort
Forty-one percent of the cohort was male (Table 1) ; 23.7 % of men and 18.9 % of women had albuminuria. As compared with participants without albuminuria, those with albuminuria were older, expended less energy, had a history of falling more often in the past year, and were more likely to be frail or prefrail. They did not report more fractures prior to the entry visit.
Other factors (BMI, alcohol use, and race) differed in relationship with albuminuria between men and women.
Crude outcome rates Participants with albuminuiria had more hip fractures and had them earlier in follow-up than participants without albuminuria (Tables 1 and 2 ); 98 men (7.7 %) had a hip fracture during a median of 8.04 years of follow-up (interquartile range (IQ), 4.11-11.31 years) and 215 women (11.7 %) had a hip fracture during a median of 9.50 years of follow-up (IQ, 5.42-11.42 years). The incidence rates of hip fracture for men, with and without albuminuria, were 1.43 and 0.93/100 personyears of follow-up, respectively. For women, the incidence rates were 1.84 and 1.33/100 person-years, respectively. For each gender, the log rank test (Fig. 1) shows significantly different event curves based on albuminuria status (p=0.02 for men and p=0.04 for women).
Adjusted outcome rates
In unadjusted Cox proportional hazard models ( 
BMD subcohort
Among men in the DEXA sub-cohort, a doubling of albuminuria (adjusted for age, race, smoking status, kilocalories energy expenditure, BMI, ecGFR, and diabetes) was associated with a lower total hip BMD but not a lower femoral neck BMD (Table 4 ). There was no association of albuminuria with hip BMD measures in women. Owing to the small number of hip fractures in this group (n = 75), the association with albuminuria was not examined in this subgroup.
Discussion
In this longitudinal study of older men and women, a doubling of albuminuria level on a baseline examination was associated with a small, but statistically significant, increased risk of incident hip fracture over 9.5 years of follow-up. With adjustment for factors related to osteoporosis, this association was attenuated. When, however, the effects of frailty and a history of falling in the year prior to study entry were adjusted for, albuminuria retained a small, but statistically significant, association with hip fracture risk in women, but not in men. Given the small effect of albuminuria on hip fracture risk, it is The results of this study are similar to those of the other two studies that have examined the relationship of albuminuria with fracture risk. In a population study from Norway [10] , a one standard deviation increase in albuminuria resulted in a relative risk of nonvertebral fracture of 1.01 in men (p=0.94) and 1.15 in women (p=0.005). In the ONTARGET/TRANSCEND Studies [10] , which examined people at high risk for CVD, baseline albuminuria predicted an increased risk of hip and pelvic fractures (HR, 1.36 (1.01, 1.84) ) in men and women, though the association appeared stronger with macroalbuminuria (HR, 1.71 (1.007, 2.91), p=0.05) than with microalbuminuria (HR, 1.28 (.92, 1.78), p=0.15) . The risk estimates from those studies are similar to those of the current study. In those studies, fractures were examined in people ∼15-20 years younger than in our cohort. At such a relatively young age, albuminuria, hip fracture, or both, may differ in character from such factors in the elderly and would not necessarily reflect the same processes. For example, in the population study from Norway, only a small percent of the cohort had microalbuminuria. In our cohort, ∼21 % had microalbuminuria. Similarly, in the cohorts from Norway and from ONTARGET/TRANSCEND, hip fractures (±pelvic fractures) occurred in ∼1.7 and .12 %, respectively, whereas in our cohort hip fractures occurred in ∼10 %. Despite these differences, a degree of similarity in risk of hip fracture in relation to albuminuria is present, making our findings believable.
We note that albuminuria was not significantly associated with hip fracture risk after adjustment for osteoporosis risk factors. This suggests that the effect of albuminuria on fracture risk was in part through osteoporosis. It was only after additional adjustment for frailty and a history of falling that the risk for fracture attained statistical significance in women, though the overall risk estimate remained approximately the same. Women with albuminuria had more frailty and falling than women without albuminuria, and even more than men, with or without albuminuria. The frailty phenotype consists mostly of low grip strength and slow walking, which are factors that predict adverse health outcomes independent of advancing age, chronic disease, and functional limitations [17, 18] . From these findings, one can speculate that albuminuria leads to fracture risk in women through musculoskeletal "senescence," which is in the causal pathway to fractures. Since menopause is accompanied by loss of muscle mass and strength [19] , any adverse impact of albuminuria on the musculoskeletal system can further increase musculoskeletal dysfunction.
Albuminuria was related to a mildly lower total hip BMD in men but not in women. This finding has a parallel in the population study from Norway [9] . In that study, BMD in the distal forearm-a site of trabecular bone-was lower in men (p=0.01) with albuminuria, but not in women. Why albuminuria was more strongly associated with BMD in men as compared with women is not certain. It may be speculated that the preceding menopausal state leads to significant loss of BMD in women which overshadows any small effect of albuminuria on BMD in older age. Among older men, who have not experienced a similar period of rapid mineral loss, the impact of increased urine albumin levels on BMD may be more noticeable. Despite this finding, albuminuria was not associated with increased fracture risk in men.
Strengths of this study include information on many aspects of participants' health, adjustment for many covariates, a high degree of quality control, the use of cystatin to estimate GFR, and prolonged follow-up. The cohort was racially mixed as compared with the homogenous cohort from Norway, an area known for high fracture risk. Three limitations should be noted. First, the participants with albuminuria testing were healthier than those who did not have albuminuria testing. Had sicker individuals been included it is likely that more albuminuria and more fractures would have been detected. Our results are therefore conservative estimates. Second, only one urine specimen was obtained at baseline, a common practice in epidemiological studies, so as to avoid extra cost and burden to participants. Albuminuria levels are known to vary. Because of this variability, we believe that our observations underestimate the true association and are biased to the null. Lastly, the participants with DEXA scanning were healthier relative to those who did not have DEXA scanning. Were sicker individuals examined it is possible that a stronger negative relationship between albuminuria and BMD could have been detected.
In conclusion, we report that albuminuria is associated with a small, independent, increased risk of hip fracture in women. This small effect cannot be used clinically for prognostic purposes. Nonetheless, the findings suggest that microvascular disease contributes to hip fracture risk in older adults. 
